Front Page News
The 2016 Annual SMA Conference is Here!
The 2016 Annual SMA Conference, now in its 28th year, is set to kick off on June 16 and continue into a weekend full of […]
Cure SMA Awards $304,000 Drug Discovery Grant to Livio Pellizzoni, PhD, at Columbia University
Cure SMA has awarded a $304,000 drug discovery grant to Livio Pellizzoni, PhD, at Columbia University. The award is for the project, “Pharmacological Inhibition of […]
Cure SMA Receives 2016 NIH Grant
For the eighth consecutive year, Cure SMA has received a grant from the National Institutes of Health (NIH) for the SMA Researcher Meeting. This year’s […]
Cure SMA Announces Biogen as Presenting Sponsor for the 2016 Annual SMA Conference
Cure SMA is pleased to announce that Biogen will be the Presenting Sponsor for our 2016 Annual SMA Conference. This year’s conference is set to […]
Cure SMA Releases June 2016 Update to the SMA Drug Pipeline
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 18 active programs. 14 pharmaceutical partners. 6 programs in clinical trials. […]
Thank you to Our 2016 Annual SMA Conference Exhibitors!
Thank you to the following exhibitors who have generously supported our 2016 Annual SMA Conference. This one-of-a-kind event would not be possible without your support! […]
Biogen and Ionis Release Spring 2016 Community Update
Biogen and Ionis Pharmaceuticals recently provided an update on the clinical development of nusinersen (IONIS-SMNRx), which is currently being tested in Phase 3 clinical trials: […]
2016 Update on SMA-FDA Interactions
The SMA drug pipeline has grown dramatically in just over a decade. Of the 18 programs in the pipeline, six of these are in clinical […]
2016 Annual SMA Conference Booklet Now Posted
The 2016 Annual SMA Conference Booklet has been posted. The booklet includes: A complete schedule with information about the special events we’ve got planned for […]
Update on the Clinical Development of LMI070
Novartis recently provided the following update on clinical trials for LMI070, an orally available SMA drug that corrects SMN2 splicing: “We have made the difficult […]